Latest & greatest articles for measles

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on measles or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on measles and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for measles

1. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.

Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. BACKGROUND: Chikungunya fever is an emerging viral disease and substantial threat to public health. We aimed to assess the safety, tolerability, and immunogenicity of a live-attenuated, measles-vectored chikungunya vaccine (MV-CHIK). METHODS: In this double-blind, randomised, placebo-controlled and active (...) -controlled phase 2 trial, we enrolled healthy volunteers aged 18-55 years at four study sites in Austria and Germany. Participants were randomly assigned to receive intramuscular injections with MV-CHIK (5 × 10 4 or 5 × 10 5 50% tissue culture infectious dose), control vaccine, or measles prime and MV-CHIK, in two different administration regimens. Randomisation was done by use of three-digit randomisation codes in envelopes provided by a data management service. The participants and investigators were

Lancet2018

2. Dealing with a measles outbreak cost 20 times that of increasing vaccination cover

Dealing with a measles outbreak cost 20 times that of increasing vaccination cover Signal - Dealing with a measles outbreak cost 20 times that of increasing vaccination cover Dissemination Centre Discover Portal NIHR DC Discover Dealing with a measles outbreak cost 20 times that of increasing vaccination cover Published on 7 June 2016 New research show that the total cost of the 2012-13 measles outbreak in Merseyside (£4.4 million) was more than twenty times the cost of the vaccinations (...) that could have prevented it (£182,909). The cost incorporated for the first time estimates of lost employment from having measles or looking after someone with it, and accounted for 44% (£2 million) of the total. Other costs included treatment of patients and public health costs, such as tracing and vaccinating people in contact with measles cases. Measles vaccinations work, but need to reach 95% or more of a group to prevent measles outbreaks in the population. If the proportion of vaccinated people

NIHR Dissemination Centre2018

3. Measles infection

Measles infection Measles infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Measles infection Last reviewed: August 2018 Last updated: September 2018 Important updates Measles infections hit record high in WHO European Region The World Health Organization (WHO) has reported that more than 41,000 children and adults in the WHO European Region were infected with measles during the first 6 months of 2018 (...) , with reports indicating that at least 37 people died following measles infection during this period. The WHO had previously reported that measles had rebounded in Europe; following a record low of 5273 measles infections in 2016, there was a fourfold increase in 2017, with 23,927 infections. Between January and June 2018, more than 41,000 infections were reported; this number far exceeds the annual total for every year since 2010. Seven countries in the WHO European Region have reported over 1000

BMJ Best Practice2018

4. Measles

Measles Top results for measles - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for measles The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

5. Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Co-Administered with Measles, Yellow Fever and Meningitis A Vaccines in 9-month-old Malian Infants

Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Co-Administered with Measles, Yellow Fever and Meningitis A Vaccines in 9-month-old Malian Infants 29659924 2018 04 20 1537-6613 2018 Apr 12 The Journal of infectious diseases J. Infect. Dis. Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Co-Administered with Measles, Yellow Fever and Meningitis A Vaccines in 9-month-old Malian Infants. 10.1093/infdis/jiy215 Rotavirus vaccines given to infants are safe and efficacious (...) . A booster dose of rotavirus vaccine could extend protection into the second year of life in low resource countries. We conducted an open-label, individual-randomized trial in Bamako, Mali. We assigned 600 9- to 11-month old infants to measles (MV), yellow fever (YFV), and meningococcal A conjugate vaccines with or without pentavalent rotavirus vaccine (PRV). We assessed non-inferiority of seroconversion and seroresponse rates (<10% difference) to MV, YFV and MenAV. We compared the seroresponse to PRV

EvidenceUpdates2018

6. Dealing with a measles outbreak cost 20 times that of increasing vaccination cover

Dealing with a measles outbreak cost 20 times that of increasing vaccination cover NIHR DC | Signal - Dealing with a measles outbreak cost 20 times that of increasing vaccination cover Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Dealing with a measles outbreak cost 20 times that of increasing vaccination cover Published on 7 June 2016 New research show that the total cost of the 2012-13 measles outbreak in Merseyside (£4.4 million) was more than twenty times the cost (...) of the vaccinations that could have prevented it (£182,909). The cost incorporated for the first time estimates of lost employment from having measles or looking after someone with it, and accounted for 44% (£2 million) of the total. Other costs included treatment of patients and public health costs, such as tracing and vaccinating people in contact with measles cases. Measles vaccinations work, but need to reach 95% or more of a group to prevent measles outbreaks in the population. If the proportion

NIHR Dissemination Centre2018

7. Measles infection

Measles infection Measles infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Measles infection Last reviewed: August 2018 Last updated: September 2018 Important updates Measles infections hit record high in WHO European Region The World Health Organization (WHO) has reported that more than 41,000 children and adults in the WHO European Region were infected with measles during the first 6 months of 2018 (...) , with reports indicating that at least 37 people died following measles infection during this period. The WHO had previously reported that measles had rebounded in Europe; following a record low of 5273 measles infections in 2016, there was a fourfold increase in 2017, with 23,927 infections. Between January and June 2018, more than 41,000 infections were reported; this number far exceeds the annual total for every year since 2010. Seven countries in the WHO European Region have reported over 1000

BMJ Best Practice2018

8. Progress towards regional measles elimination – worldwide, 2000–2016 – Progrès accomplis dans le monde en vue de l’élimination régionale de la rougeole, 2000-2016

Progress towards regional measles elimination – worldwide, 2000–2016 – Progrès accomplis dans le monde en vue de l’élimination régionale de la rougeole, 2000-2016 WHO IRIS: Progress towards regional measles elimination – worldwide, 2000–2016 – Progrès accomplis dans le monde en vue de l’élimination régionale de la rougeole, 2000-2016 Browse Related links Files in This Item: File Description Size Format 530.09 kB Adobe PDF Title: Progress towards regional measles elimination – worldwide, 2000

WHO2017

9. Measles virus envelope pseudotyped lentiviral vectors transduce quiescent human HSCs at an efficiency without precedent

Measles virus envelope pseudotyped lentiviral vectors transduce quiescent human HSCs at an efficiency without precedent 29296856 2018 11 13 2473-9529 1 23 2017 Oct 24 Blood advances Blood Adv Measles virus envelope pseudotyped lentiviral vectors transduce quiescent human HSCs at an efficiency without precedent. 2088-2104 10.1182/bloodadvances.2017007773 Hematopoietic stem cell (HSC)-based gene therapy trials are now moving toward the use of lentiviral vectors (LVs) with success. However, one (...) challenge in the field remains: efficient transduction of HSCs without compromising their stem cell potential. Here we showed that measles virus glycoprotein-displaying LVs (hemagglutinin and fusion protein LVs [H/F-LVs]) were capable of transducing 100% of early-acting cytokine-stimulated human CD34 + (hCD34 + ) progenitor cells upon a single application. Strikingly, these H/F-LVs also allowed transduction of up to 70% of nonstimulated quiescent hCD34 + cells, whereas conventional vesicular stomatitis

Blood advances2017 Full Text: Link to full Text with Trip Pro

10. Incidence of Measles in the United States, 2001–2015

Incidence of Measles in the United States, 2001–2015 28973240 2017 10 23 2018 11 13 1538-3598 318 13 2017 10 03 JAMA JAMA Incidence of Measles in the United States, 2001-2015. 1279-1281 10.1001/jama.2017.9984 Clemmons Nakia S NS Division of Viral Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia. Wallace Gregory S GS Division of Viral Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia. Patel Manisha M Division of Viral Diseases, US Centers (...) for Disease Control and Prevention, Atlanta, Georgia. Gastañaduy Paul A PA Division of Viral Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia. eng CC999999 Intramural CDC HHS United States Journal Article United States JAMA 7501160 0098-7484 0 Measles Vaccine AIM IM J Infect Dis. 2004 May 1;189 Suppl 1:S23-6 15106085 JAMA Pediatr. 2014 Feb;168(2):148-55 24311021 MMWR Morb Mortal Wkly Rep. 2015 Nov 13;64(44):1246-51 26562349 J Pediatric Infect Dis Soc. 2017 Mar 1;6(1):40-48

JAMA2017 Full Text: Link to full Text with Trip Pro

11. Chickenpox and measles clusters among college students in Pune, Maharashtra

Chickenpox and measles clusters among college students in Pune, Maharashtra 29291222 2018 11 13 2347-3584 28 3 2017 Sep Virusdisease Virusdisease Chickenpox and measles clusters among college students in Pune, Maharashtra. 337-340 10.1007/s13337-017-0395-3 Chickenpox and measles, both vaccine preventable febrile rash illnesses, present in a comparatively severe form among young adults/adults than among children. Immunity levels against chickenpox are not known in India and those against measles (...) that it was a case of two parallel outbreaks of chickenpox and measles. In this outbreak chickenpox cases did not present with greater severity but measles cases were severe. The concerned institute hosts more than 800 students and 300 staff including faculty. These outbreaks were contained because of the alert physician in the institute; but it also highlights a need for uniform policies across such educational institutions in the country. Deoshatwar Avinash R AR National Institute of Virology [NIV], Indian

Virusdisease2017 Full Text: Link to full Text with Trip Pro

12. Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands.

Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands. Objectives To investigate whether measles, mumps, and rubella (MMR) vaccine has positive non-specific effects in a high income setting and to compare rates of hospital admissions for infections between children aged ≤2 years who received live MMR vaccine and those who received an inactivated vaccine against diphtheria, tetanus, pertussis, polio (...) , and Haemophilus influenzae type b (DTaP-IPV-Hib) as their most recent vaccination. Design Nationwide population based cohort study. Setting In the Netherlands, DTaP-IPV-Hib+pneumococcal vaccination (PCV) is recommended at ages 2, 3, 4, and 11 months and MMR + meningococcal C (MenC) vaccination at age 14 months. Data from the national vaccine register were linked to hospital admission data. Participants 1 096 594 children born in 2005-11 who received the first four DTaP-IPV-Hib+PCV vaccines. Main outcome

BMJ2017

13. A killer nailed: a reconstruction of Maldives triumph over measles.

A killer nailed: a reconstruction of Maldives triumph over measles. WHO IRIS: A killer nailed: a reconstruction of Maldives triumph over measles. Browse Related links Files in This Item: File Description Size Format 3.34 MB Adobe PDF Title: A killer nailed: a reconstruction of Maldives triumph over measles. Authors: Issue Date: Aug-2017 Publisher: World Health Organization. Regional Office for South-East Asia Place of publication: New Delhi Language: English Subject: URI: ISBN: 9789290225942

WHO2017

14. Banished from Bhutan: the story of how a small mountain kingdom eliminated measles

Banished from Bhutan: the story of how a small mountain kingdom eliminated measles WHO IRIS: Banished from Bhutan: the story of how a small mountain kingdom eliminated measles Browse Related links Files in This Item: File Description Size Format 5.47 MB Adobe PDF Title: Banished from Bhutan: the story of how a small mountain kingdom eliminated measles Authors: Issue Date: Aug-2017 Publisher: World Health Organization. Regional Office for South-East Asia Place of publication: New Delhi Language

WHO2017

15. Progress towards measles elimination in Bangladesh, 2000–2016– Progrès réalisés en vue d’éliminer la rougeole au Bangladesh, 2000-2016

Progress towards measles elimination in Bangladesh, 2000–2016– Progrès réalisés en vue d’éliminer la rougeole au Bangladesh, 2000-2016 WHO IRIS: Progress towards measles elimination in Bangladesh, 2000–2016– Progrès réalisés en vue d’éliminer la rougeole au Bangladesh, 2000-2016 Browse Related links Files in This Item: File Description Size Format 378.84 kB Adobe PDF Title: Progress towards measles elimination in Bangladesh, 2000–2016– Progrès réalisés en vue d’éliminer la rougeole au

WHO2017

16. Measles.

Measles. Measles is a highly contagious disease that results from infection with measles virus and is still responsible for more than 100 000 deaths every year, down from more than 2 million deaths annually before the introduction and widespread use of measles vaccine. Measles virus is transmitted by the respiratory route and illness begins with fever, cough, coryza, and conjunctivitis followed by a characteristic rash. Complications of measles affect most organ systems, with pneumonia (...) accounting for most measles-associated morbidity and mortality. The management of patients with measles includes provision of vitamin A. Measles is best prevented through vaccination, and the major reductions in measles incidence and mortality have renewed interest in regional elimination and global eradication. However, urgent efforts are needed to increase stagnating global coverage with two doses of measles vaccine through advocacy, education, and the strengthening of routine immunisation systems. Use

Lancet2017

17. Zinc supplementation for the treatment of measles in children.

Zinc supplementation for the treatment of measles in children. BACKGROUND: Measles is an important cause of childhood morbidity and mortality globally, despite increasing vaccine coverage. Zinc plays a significant role in the maintenance of normal immunological functions, therefore supplements given to zinc-deficient children will increase the availability of zinc and could reduce measles-related morbidity and mortality. This is an update of a review first published in 2015. OBJECTIVES (...) : To assess the effects of zinc supplementation in reducing morbidity and mortality in children with measles. SEARCH METHODS: We searched CENTRAL (03 February 2017, Issue 2), MEDLINE (1946 to 03 February 2017), Embase (1974 to 03 February 2017), CINAHL (1981 to 03 February 2017), LILACS (1982 to 03 February 2017), Web of Science (1985 to 03 February 2017), and BIOSIS Previews (1985 to 27 June 2014). We also searched ClinicalTrials.gov, the Australian New Zealand Clinical Trials Registry and the World

Cochrane2017

18. Missed Opportunities for Measles, Mumps, Rubella Vaccination Among Departing U.S. Adult Travelers Receiving Pretravel Health Consultations.

Missed Opportunities for Measles, Mumps, Rubella Vaccination Among Departing U.S. Adult Travelers Receiving Pretravel Health Consultations. Background: Measles outbreaks continue to occur in the United States and are mostly due to infections in returning travelers. Objective: To describe how providers assessed the measles immunity status of departing U.S. adult travelers seeking pretravel consultation and to assess reasons given for nonvaccination among those considered eligible to receive (...) the measles, mumps, rubella (MMR) vaccine. Design: Observational study in U.S. pretravel clinics. Setting: 24 sites associated with Global TravEpiNet (GTEN), a Centers for Disease Control and Prevention-funded consortium. Patients: Adults (born in or after 1957) attending pretravel consultations at GTEN sites (2009 to 2014). Measurements: Structured questionnaire completed by traveler and provider during pretravel consultation. Results: 40 810 adult travelers were included; providers considered 6612 (16%) to be eligible

Annals of Internal Medicine2017

19. Measles-Rubella Bulletin - Vol 11 Issue 1

Measles-Rubella Bulletin - Vol 11 Issue 1 WHO IRIS: Measles-Rubella Bulletin - Vol 11 Issue 1 Browse Related links Files in This Item: File Description Size Format 2.58 MB Adobe PDF Title: Measles-Rubella Bulletin - Vol 11 Issue 1 Authors: Issue Date: Jan-2017 Publisher: Manila : WHO Regional Office for the Western Pacific Language: English Description: 10 p. Subject: Context: statistics and numerical data URI: ISSN: 1814 3601 Appears in Collections: Items in WHO IRIS are protected by copyright

WHO2017

20. Public-health impact of accelerated measles control in the WHO African Region 2000-03.

Public-health impact of accelerated measles control in the WHO African Region 2000-03. BACKGROUND: In 2000, the WHO African Region adopted a plan to accelerate efforts to lower measles mortality with the goal of decreasing the number of measles deaths to near zero. By June, 2003, 19 African countries had completed measles supplemental immunisation activities (SIA) in children aged 9 months to 14 years as part of a comprehensive measles-control strategy. We assessed the public-health impact (...) of these control measures by use of available surveillance data. METHODS: We calculated percentage decline in reported measles cases during 1-2 years after SIA, compared with 6 years before SIA. On the basis of data from 13 of the 19 countries, we assumed that the percentage decline in measles deaths equalled that in measles cases. We also examined data on routine and SIA measles vaccine coverage, measles case-based surveillance, and suspected measles outbreaks. FINDINGS: Between 2000 and June, 2003, 82.1

Lancet2017